Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

AMRX holding history

Amneal Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AMRX overviewAll 13F holders of AMRXFull Q2 2026 holdings

Shares (Q2 2026)
444,400
Value
$7.69M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of AMRX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026444,400$7.69M<0.1%−396,558−47.2%ReducedHolders
Q1 2026840,958$10.5M<0.1%−94,521−10.1%ReducedHolders
Q4 2025935,479$11.8M<0.1%−510,322−35.3%ReducedHolders
Q3 20251,445,801$14.5M<0.1%−136,949−8.7%ReducedHolders
Q2 20251,582,750$12.8M<0.1%−229,625−12.7%ReducedHolders
Q1 20251,812,375$15.2M<0.1%+146,850+8.8%AddedHolders
Q4 20241,665,525$13.2M<0.1%−20,107,524−92.4%ReducedHolders
Q3 202421,773,049$181.2M0.1%−76,474−0.4%ReducedHolders
Q2 202421,849,523$138.7M<0.1%+21,671,365+12,164.1%AddedHolders
Q1 2024178,158$1.08M<0.1%+3,931+2.3%AddedHolders
Q4 2023174,227$1.06M<0.1%+105,809+154.7%AddedHolders
Q3 202368,418$288.7K<0.1%+56,529+475.5%AddedHolders
Q2 202311,889$36.9K<0.1%+6,644+126.7%AddedHolders
Q1 20235,245$7.29K<0.1%−13,738−72.4%ReducedHolders
Q4 202218,983$37.8K<0.1%−7,592−28.6%ReducedHolders
Q3 202226,575$54.0K<0.1%+15,430+138.4%AddedHolders
Q2 202211,145$35.0K<0.1%−1,193−9.7%ReducedHolders
Q1 202212,338$51.0K<0.1%−24,982−66.9%ReducedHolders
Q4 202137,320$178.0K<0.1%+26,320+239.3%AddedHolders
Q3 202111,000$59.0K<0.1%−9,242−45.7%ReducedHolders
Q2 202120,242$103.0K<0.1%+9,242+84.0%AddedHolders
Q1 202111,000$74.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.